Johnson & Johnson $JNJ Shares Sold by HighTower Advisors LLC

Key Points

• HighTower Advisors reduced its Johnson & Johnson stake by 5.6% in the second quarter, selling 591,434 shares but retaining nearly 9.9 million shares worth approximately $2.51 billion. Institutional investors collectively own 69.55% of J&J.
• Analyst sentiment remains favorable, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $274.13. J&J recently exceeded quarterly earnings and revenue expectations, reporting $2.90 EPS and $25.31 billion in revenue.
• J&J paid a quarterly dividend of $1.34 per share, equivalent to a 2.0% annualized yield. Meanwhile, insiders sold 87,569 shares worth about $23.1 million over the past 90 days, while the stock recently traded near $266.94.

HighTower Advisors LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,892,767 shares of the company's stock after selling 591,434 shares during the period. Johnson & Johnson comprises about 2.4% of HighTower Advisors LLC's investment portfolio, making the stock its 4th biggest holding. HighTower Advisors LLC owned about 0.41% of Johnson & Johnson worth $2,512,466,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of JNJ. Silver Coast Investments LLC lifted its holdings in shares of Johnson & Johnson by 3.8% in the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock valued at $271,000 after purchasing an additional 39 shares in the last quarter. Townsend Asset Management Corp NC ADV lifted its stake in Johnson & Johnson by 0.6% in the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock worth $1,630,000 after acquiring an additional 39 shares in the last quarter. Triumph Capital Management boosted its position in Johnson & Johnson by 1.6% during the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company's stock worth $643,000 after acquiring an additional 39 shares during the period. Denali Advisors LLC grew its stake in Johnson & Johnson by 1.2% during the 2nd quarter. Denali Advisors LLC now owns 3,305 shares of the company's stock valued at $839,000 after acquiring an additional 40 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC lifted its position in shares of Johnson & Johnson by 1.8% in the fourth quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company's stock worth $501,000 after purchasing an additional 42 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares of the company's stock, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. The Goldman Sachs Group reiterated a "buy" rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Citigroup boosted their target price on Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. Argus set a $300.00 price target on Johnson & Johnson in a report on Wednesday, July 29th. Bank of America raised their price objective on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a "neutral" rating in a research report on Friday, July 10th. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $274.13.

Johnson & Johnson Price Performance

NYSE JNJ opened at $266.94 on Wednesday. Johnson & Johnson has a 1 year low of $173.33 and a 1 year high of $281.07. The company has a fifty day simple moving average of $263.17 and a 200 day simple moving average of $246.23. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a market cap of $643.29 billion, a P/E ratio of 30.93, a P/E/G ratio of 2.54 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same quarter in the previous year, the business earned $2.77 EPS. The business's revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is currently 62.11%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Potential $20 billion DePuy Synthes sale could unlock value. Apollo Global Management is reportedly in talks to acquire J&J’s DePuy Synthes orthopedics business, which generated approximately $9.3 billion in 2025 revenue. A sale or spinoff could sharpen J&J’s focus and return capital to shareholders. Apollo and J&J Face a High-Stakes Orthopedics Deal
• Positive Sentiment: Rybrevant delivers strong lung-cancer results. J&J reported that Rybrevant plus chemotherapy produced a 34.3-month median overall survival in EGFR exon 20 insertion-positive non-small-cell lung cancer, described as the longest reported result for this population. Separate data also showed fewer treatment-related events with the Rybrevant Faspro and Lazcluze combination, supporting the oncology pipeline and potential commercial momentum. Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
• Positive Sentiment: Analyst and defensive-investment support remain favorable. TD Cowen maintained a Buy rating with a $300 price target, citing oncology momentum and the possible DePuy Synthes transaction. J&J is also being highlighted as a reliable dividend and defensive healthcare holding, which may attract investors during market volatility. J&J: Oncology Momentum and Potential $20B DePuy Synthes Divestiture Support Buy Rating
• Neutral Sentiment: Investors are monitoring strategic and fundamental developments. Attention is focused on J&J’s ability to achieve double-digit growth while Stelara faces biosimilar competition. Recent institutional activity has been mixed, while reported insider transactions consisted entirely of sales over the past six months.
• Negative Sentiment: Clinical setback hits a partnered depression treatment. JNJ-5120, also known as PIPE-307, failed to meet the primary endpoint in the Phase 2 MOONLIGHT-1 trial for major depressive disorder. J&J is reviewing additional data, but the failure reduces confidence in this portion of its drug-development pipeline. Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.